Therefore, it is not surprising that no significant differences were observed in atrial fibrillation, aortic aneurysm, VHD, conduction disorders, peripheral artery disease, cor pulmonale, and venous thromboembolism events, since these events have not been established in prior CV outcome trials of GLP-1 RA. This evidence concerns the gene GCG and peripheral arterial disease.